C. diff Risk


Oral Bioavailability


Approximate Cost


300-450mg IV q8h for usual indications 900mg IV q8h for necrotizing skin/soft tissue infections or toxic shock syndrome 300-450mg PO TID

General Information

Common Usage

Anaerobic infections above the diaphragm, especially dental infection.

Gram positive skin and soft tissue infections including necrotizing fasciitis as an adjunctive agent to a beta lactam for reducing toxin production.

Skin & soft tissue infections involving susceptible MRSA.

Susceptible infections and surgical prophylaxis in setting of IgE mediated beta-lactam allergy.

For decreasing toxin production in toxic shock syndrome.

Drug Monitoring

None specific - monitor for diarrhea.

Adverse Effects

High risk of Clostridium difficile infection

Major Interactions

Muscle relaxants, e.g., atracurium, baclofen, diazepam

St. Johns Wort


Antimicrobial class: Lincosamide

Pregnancy category: B

Average serum half life: 2.4

Biliary penetration: Therapeutic

CSF penetration: Poor

Lung penetration: Therapeutic

Urine penetration: Poor